Theradaptive, a Frederick, MD-based biopharmaceutical company focused on targeted regenerative therapeutics, raised $26M in Series A funding.
The round brought the total funding to over $50M. The backers were not disclosed.
The company intends to use the funds to advance development of its targeted regenerative therapeutics, to continue its work to meet regulatory requirements, to scale up manufacturing practices in preparation for first-in-human clinical trials later this year, and to expand the platform beyond orthopedics to additional indications such as oncology and dental.
Founded in 2016, Theradaptive is a biopharmaceutical and medical device company leveraging its therapeutic delivery platform to develop new therapies for spine, orthopedics and soft tissue repair, as well as targeted immuno-oncology. The proprietary protein-engineering platform produces targeted therapeutics that can be used to coat implants, devices, and injectable carriers to achieve hyper-local delivery over long time periods exceeding weeks to months.
The company has previously been awarded non-dilutive grant funding from the Department of Defense, as well as the Maryland Stem Cell Research Fund.
FinSMEs
15/06/2023